It features a curved distal end, designed to improve maneuverability when applying the medical device, while eliminating the need for the commonly used Magill forceps. This ensures gentler application and less risk of injury to premature babies. RDS is a respiratory disorder resulting from surfactant deficiency and underdeveloped lungs, occurring mainly in premature babies. In Europe, it is reported in around 90% of babies born at 24 weeks and 80% of babies born at 28 weeks. Surfactant administration is an important part of RDS treatment. The currently preferred method of surfactant administration is the LISA method, which uses a thin catheter inserted through the vocal cords to avoid unnecessary intubation. This method can be performed in a number of ways, usually involving the use of Magill forceps. The design of the new Surfcath device enables healthcare professionals to insert it without the need for these forceps.